Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof

Patent metadata

Field	Value
Publication number	US-10548904-B2
Application number	US-201314045311-A
Country	US
Kind code	B2
Filing date	Oct 3, 2013
Priority date	Feb 4, 2008
Publication date	Feb 4, 2020
Grant date	Feb 4, 2020

Abstract

The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.

First claim

What is claimed is:

1. A method for supplementation or replacement of corpus luteal function, the method comprising administering progesterone to a subject by a monolithic intravaginal ring comprising a polysiloxane elastomer and a pharmaceutically acceptable hydrocarbon or glycerol ester of a fatty acid, or a polysiloxane elastomer and a pharmaceutically acceptable oil, in amounts that are effective to maintain a serum progesterone level of about 6 ng/mL to about 10 ng/mL over a 7-day period of use after administration to the subject;
wherein the polysiloxane elastomer is present in an amount of about 55% to about 90% by total weight of the ring;
wherein the pharmaceutically acceptable hydrocarbon or glycerol ester of a fatty acid or the pharmaceutically acceptable oil is present in an amount of about 1% to about 10% by total weight of the ring;
wherein the progesterone is present in an amount of about 15% to about 30% by total weight of the ring.

2. The method of claim 1 , wherein the polysiloxane elastomer is dimethylpolysiloxane elastomer.

3. The method of claim 1 , wherein the polysiloxane elastomer is a dimethylpolysiloxane elastomer, and wherein the ratio by weight of progesterone to elastomer is about 1:1 to about 1:10, the progesterone is homogeneously dispersed in the elastomer, and the ratio of progesterone to hydrocarbon or glycerol esters of a fatty acid is about 1:0.1 to about 1:100.

4. The method of claim 2 , wherein the intravaginal ring comprises:
(a) about 15% to about 25% by weight of the progesterone;
(b) about 70% to about 80% by weight of the dimethylpolysiloxane elastomer; and
(c) about 1% to about 10% by weight of the pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid or the pharmaceutically acceptable oil,
wherein the progesterone is homogeneously dispersed in the elastomer.

5. The method of claim 1 , wherein the intravaginal ring releases progesterone at a steady rate over a 7-day period of use.

6. The method of claim 1 , wherein the intravaginal ring releases about 11 mg to about 15 mg progesterone per day at a steady state rate over a 7-day period of use.

7. The method of claim 1 , wherein the pharmaceutically acceptable oil is mineral oil.

8. The method of claim 1 , wherein the intravaginal ring comprises the progesterone, the dimethylpolysiloxane elastomer, and the pharmaceutically acceptable oil, in a ratio by weight of about 4:15:1, respectively, wherein the progesterone is homogeneously dispersed in the elastomer.

9. A method for treating a luteal phase defect or supporting embryo implantation and early pregnancy in a patient in need thereof, the method comprising administering progesterone to a vaginal and/or urogenital tract of a subject, in amounts that are effective to maintain a serum progesterone level of about 6 ng/mL to about 10 ng/mL over a 7-day period of use, wherein said progesterone is administered by a monolithic intravaginal ring comprising a polysiloxane elastomer and a pharmaceutically acceptable hydrocarbon or glycerol ester of a fatty acid or a polysiloxane elastomer and a pharmaceutically acceptable oil, wherein:
the polysiloxane elastomer is present in an amount of about 55% to about 90% by total weight of the ring;
the pharmaceutically acceptable hydrocarbon or glycerol ester of a fatty acid or the pharmaceutically acceptable oil is present in an amount of about 1% to about 10% by total weight of the ring; and
the progesterone is present in an amount of about 15% to about 30% by total weight of the ring.

10. The method according to claim 1 , said method further comprising replacing the monolithic intravaginal ring about 7 days after administration to the subject.

11. The method according to claim 1 , wherein the subject is a woman with progesterone deficiency.

12. The method of claim 2 , wherein the intravaginal ring consists of:
(a) about 15% to about 25% by weight of the progesterone;
(b) about 70% to about 80% by weight of the dimethylpolysiloxane elastomer; and
(c) about 1% to about 10% by weight of the pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid or the pharmaceutically acceptable oil,
wherein the progesterone is homogeneously dispersed in the elastomer.

Assignees

• Ferring Bv

Inventors

• Ahmed Salah U
• Tsao Jiaxiang
• Mahashabde Anu
• Harrison Diane D

Classifications

• A61P5/34

  Gestagens · CPC title

• A61P5/24

  of the sex hormones · CPC title

• A61P5/06

  of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH · CPC title

• A61P15/18

  Feminine contraceptives · CPC title

• A61P15/08

  for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis · CPC title